Compare Adaptive Biotechnologies Corp (ADPT) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Canadian Natural Resources Ltd. — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Canadian Natural Resources Ltd. trades at $42.25 (market cap $84.83B). The key difference: Canadian Natural Resources Ltd. is far larger — about 25.5× Adaptive Biotechnologies Corp's market cap, and Canadian Natural Resources Ltd. pays a 4.32% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CNQ | |
|---|---|---|
Market Cap | $3.33B | $84.83B |
Sector | Health | Energy |
52-Week High | $22.37 | $50.55 |
52-Week Low | $10.24 | $29.31 |
Enterprise Value | $3.19B | $96.06B |
Dividend Yield | — | 4.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Canadian Natural Resources (CNQ) trades at $40.69, up 2.65% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows attractive valuation metrics with P/E of 11.8 and robust profitability including 24.5% net margin. Technical indicators signal bearish sentiment despite recent price strength, while analyst consensus remains overwhelmingly positive with 75% buy ratings. Recent dividend declarations and strong cash flow generation support shareholder returns.
CNQ presents a compelling value opportunity with solid fundamentals and positive earnings surprises, though technical weakness and oil price volatility pose near-term risks. The company's strong balance sheet and consistent dividend payments provide downside protection, while operational efficiency and production growth drive long-term potential. Investors should weigh valuation appeal against energy sector cyclicality and technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
